Literature DB >> 9328344

Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism.

S Xu1, S Khoo, A Dang, S Witt, V Do, E Zhen, E M Schaefer, M H Cobb.   

Abstract

Mitogen-activated protein (MAP)/ERK kinase (MEK)1 and MEK2 are the upstream activators of the MAP kinases, ERK1 and ERK2. MEK1 and MEK2 are approximately 85% identical in sequence but have unique inserts in their C-terminal domains. MEK isoform-specific antibodies were used to examine expression and regulation of each enzyme. MEK1 and MEK2 were expressed in approximately equal amounts in several cell lines; in some, MEK1 was present in slight excess. Activation of tyrosine kinase-containing receptors, heterotrimeric G proteins, and protein kinase C enhanced the activities of both MEK isoforms in 293 and PC12 cells. AIF4-stimulated both MEK1 and MEK2 in PC12 cells expressing a dominant interfering Ras mutant that prevents nerve growth factor-dependent activation of the cascade. Carbachol also stimulated the pathway in these cells. Thus, in addition to their ability to activate Ras/Raf and the downstream ERK pathway, heterotrimeric G proteins also appear to trigger a Ras-independent mechanism to regulate this kinase cascade. In U373, Chinese hamster ovary (CHO), and INS-1 cells, MEK1 was activated by regulators of ERKs, while MEK2 was not. These data suggest that, like the MAP kinases ERK1 and ERK2, in some cell settings the two similar MEK isoforms are differentially regulated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328344     DOI: 10.1210/mend.11.11.0010

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  9 in total

1.  Activation of B-Raf and regulation of the mitogen-activated protein kinase pathway by the G(o) alpha chain.

Authors:  V Antonelli; F Bernasconi; Y H Wong; L Vallar
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

2.  MEK inhibition suppresses the development of lung fibrosis in the bleomycin model.

Authors:  Maria Galuppo; Emanuela Esposito; Emanuela Mazzon; Rosanna Di Paola; Irene Paterniti; Daniela Impellizzeri; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

3.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 4.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors:  Christophe Frémin; Sylvain Meloche
Journal:  J Hematol Oncol       Date:  2010-02-11       Impact factor: 17.388

5.  GalNAc/Gal-binding Rhizoctonia solani agglutinin has antiproliferative activity in Drosophila melanogaster S2 cells via MAPK and JAK/STAT signaling.

Authors:  Mohamad Hamshou; Els J M Van Damme; Gianni Vandenborre; Bart Ghesquière; Geert Trooskens; Kris Gevaert; Guy Smagghe
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

Review 6.  Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations.

Authors:  Emilio Francesco Giunta; Vincenzo De Falco; Stefania Napolitano; Giuseppe Argenziano; Gabriella Brancaccio; Elvira Moscarella; Davide Ciardiello; Fortunato Ciardiello; Teresa Troiani
Journal:  Ther Adv Med Oncol       Date:  2020-06-19       Impact factor: 8.168

7.  Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation.

Authors:  Jordan M Baumhardt; Janek S Walker; Yoonji Lee; Binita Shakya; Chad A Brautigam; Rosa Lapalombella; Nick Grishin; Yuh Min Chook
Journal:  Mol Biol Cell       Date:  2020-06-10       Impact factor: 4.138

8.  Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.

Authors:  Laure Voisin; Catherine Julien; Stéphanie Duhamel; Kailesh Gopalbhai; Isabelle Claveau; Marc K Saba-El-Leil; Ian Gaël Rodrigue-Gervais; Louis Gaboury; Daniel Lamarre; Mark Basik; Sylvain Meloche
Journal:  BMC Cancer       Date:  2008-11-17       Impact factor: 4.430

Review 9.  The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.

Authors:  Jimin Yuan; Xiaoduo Dong; Jiajun Yap; Jiancheng Hu
Journal:  J Hematol Oncol       Date:  2020-08-17       Impact factor: 17.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.